Funding and independence: who pays for this site

In short

About 4 minutes for the short version; 6 with every detail open.

  • This site sells nothing. It shows no ads and has no sponsors.
  • It takes no money from drug makers, sellers or clinics.
  • At launch, the editor pays the costs. Any future grant will be listed here, with the amount.
  • There are no ads and no ad cookies. Our host keeps visit statistics for us.
Last reviewed
An old balance with two empty metal pans hanging from a gold-coloured stand on a wooden box with two drawers.
Photo: HelgeRieder (Wikimedia Commons) CC0 1.0 Image details

Each section starts with the short answer. The rest is folded under “In detail”.

What we do not take

Does anyone pay you to write this?

No. No company pays us. We sell nothing, show no ads and earn nothing from links.
This site has no income from anyone who sells medicines, peptides or treatments. Our rules on money, as of 22 October 2026. They apply to every page and every language.
This site
Sells anything: products, tests, courses or consultations?No Nothing is for sale here.
Takes money from drug makers, peptide sellers or clinics?No Never, in any form.
Shows advertising?No No ads of any kind.
Earns money from links, or from sending readers to someone?No No paid links, no referral fees, no codes that give money off.
Has sponsors?No No sponsors and no paid partners.
Tells you where to get a product?No We name no sellers and link to none.

We link only to sites on a fixed list. It holds regulators, law databases, PubMed and science journals, universities, anti-doping bodies, patient and harm-reduction groups, and a few non-profit services, such as the archive our photos come from. No one who sells medicines or peptides can be on it. A check runs every time the site is built. It stops the build if a page links anywhere else.

Why it has to be this way

Why so strict?

The law bans ads for medicines with no licence. And money shapes what people write.
How a link to a shop could turn information into an advert.
  1. Advertising is defined by its aim. Dutch law counts any attempt to get people to prescribe, supply or use a medicine.1
  2. No licence, no advertising. Any advertising for a medicine without a licence is forbidden. So is public advertising for prescription-only medicines.2,3
  3. An independent writer can still be advertising. The EU Court of Justice ruled that what counts is the purpose of the message.4
  4. So we earn nothing from any product. Without money from sales, our information stays information.

Many peptides on this site, such as BPC-157, have no licence as a medicine in the EU.5,6 If we earned money when someone bought one, our explanations could become advertising. Our page on Dutch law explains this in more detail.

In detail: The second reason: money shapes what people write , about 1 minute to read

The law is not the only reason. Money changes which questions get asked and how answers are framed, even when everyone means well.

A Cochrane review looked at 75 papers that compared studies paid for by a drug or device maker with studies paid for by others. The maker’s studies more often reported results and conclusions that favoured the product. By the usual quality checks they were not worse designed. On one check, blinding, they did better. The authors concluded there is an “industry bias” that the usual quality checks cannot explain.7

Some of what is said about these peptides comes from people who earn money from them: sellers, clinics and paid promoters. That does not make it false. But a source that earns money when you buy has a reason to stress benefits and play down risks. We want to be one source with no such reason. That is also why our editorial policy records who paid for the research we describe.

How the site is paid for

Then who pays?

The editor pays the costs at launch. Any future grant or donation will be listed here.
Where money may come from, and what we will publish about it.
Source of moneyAccepted?What we publish
The editor’s own moneyYes, at launchThat the editor pays the costs
A grant from a public body or a charityPossibly in futureThe funder and the amount, on this page
Donations from readersOnly if we ever askThe total, on this page; donors get nothing in return
Drug makers, peptide sellers, clinics, affiliate schemesNeverNot applicable

At launch, the site has no income at all. The editor pays for hosting and tools. A funder would get no say in what we write, and no early look at any page. If that ever changes, this page will say so first.

Your privacy

Do you track me?

We do not track you ourselves. Our host keeps visit statistics, and we see only the totals.
What happens when you open a page on this site.
What you might expectWhat happens here
CookiesThree short-lived cookies from our host: against bots, for its own routing, and to group your page views into one visit. No ad cookies
Analytics or tracking scriptsOur host adds statistics scripts to every page. We see only totals, never who you are
Ads, social media buttons or videos from other sitesNone
Fonts and images from other serversNone: we serve every file ourselves
What you type in the search boxSearched in your browser. It appears in the page address, so it can reach your browser history and our host’s statistics
Your choice of light or dark displayKept in your own browser, only if you choose one

Dutch law says a website must ask before it stores or reads anything on your device. There are exceptions for what is strictly needed to give you the service you asked for, and for statistics with little or no effect on your privacy.8 Below is everything that is stored, and why.

In detail: The details , about 2 minutes to read
  • Display choice. If you switch between light and dark, your browser remembers that choice on your own device. It is never sent to us. If you never switch, nothing is stored.
  • Security cookie. Our host, Lovable, runs on Cloudflare. Cloudflare sets one cookie, called __cf_bm, to tell people from automated bots. It expires after 30 minutes. We cannot read it and do not use it.
  • Routing cookie. Our host sets a cookie called __dpl, so that every page you open comes from the same version of the site. It expires after 24 hours.
  • Visit statistics. Our host adds small statistics scripts to every page. They record the page address, the website you came from, your browser and type of device, your language, an estimated country, clicks, how long you stay, and how fast the page loads. A cookie called session-id groups your page views into one visit; it expires after 30 minutes. The data goes to our host. We see only totals in its dashboard. We add no analytics of our own and build no profiles of readers.
  • Server requests. Like every website, the server that sends you a page needs your device’s internet address to deliver it.
  • No other websites. Every file a page loads comes from this site’s own address. Links to official sources open only when you choose to follow them.
  • No accounts. You cannot log in, and we ask for no personal data.

Sources

Every claim on this page links to one of these sources. Scholarly sources link to their DOI; regulatory sources to the regulator's own page.

In detail: All 8 sources, numbered as in the text , about 2 minutes to read
  1. Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 1, eerste lid, onder hh, xx en ijij (invoeren, reclame, publieksreclame). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026 ↩
  2. Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikelen 84 en 85 (reclame; publieksreclame). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026 ↩
  3. European Parliament and Council of the European Union (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text). Official Journal of the European Communities, L 311. Law eur-lex.europa.eu (opens an external site) — accessed 20 October 2026 ↩
  4. Court of Justice of the European Communities (Second Chamber) (2009). Judgment of 2 April 2009, Criminal proceedings against Frede Damgaard, Case C-421/07. EUR-Lex (CELEX 62007CJ0421). Law eur-lex.europa.eu (opens an external site) — accessed 22 October 2026 ↩
  5. European Medicines Agency (2026). Medicines (search of centrally authorised medicines and EPARs). Regulator ema.europa.eu (opens an external site) — accessed 20 October 2026 ↩
  6. U.S. Food and Drug Administration (2026). FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov (opens an external site) — accessed 20 October 2026 ↩
  7. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2:MR000033. Review doi:10.1002/14651858.MR000033.pub3 (opens an external site) ↩
  8. Staten-Generaal / Koninkrijk der Nederlanden (1998). Telecommunicatiewet, artikel 11.7a (opslaan van of toegang tot informatie in de randapparatuur van een gebruiker). wetten.overheid.nl (BWBR0009950), version in force from 15 August 2026. Law wetten.overheid.nl (opens an external site) — accessed 22 October 2026 ↩